Stock DNA GENENTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Genentech, Inc.

Equities

DNA

US3687104063

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Genentech, Inc.
2015 Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015 CI
2009 GENENTECH : Roche buys Genentech for $46.8 billion RE

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015
CI
Genentech, Inc. : Dalradian Appoints Chief Operating Officer
PU
Genentech, Inc. : Dalradian Appoints Chief Operating Officer
PU
GENENTECH : Roche Completes Acquisition of Genentech
PR
GENENTECH : Roche Completes Tender Offer for Genentech
PR
GENENTECH : Roche buys Genentech for $46.8 billion
RE
GENENTECH : Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
PR
GENENTECH : Roche increases Genentech offer to $45.7 billion
RE
GENENTECH : Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer
PR
GENENTECH : gives long-term forecast to fend off Roche
RE
GENENTECH : to make case for higher purchase price
RE
GENENTECH : asks shareholders to hold off on Roche bid
RE
GENENTECH : Roche goes hostile, cuts Genentech bid to $42 billion
RE
GENENTECH : forecast disappoints
RE
GENENTECH : profit up, forecast light
RE
GENENTECH : profit rises, sales top estimates
RE
GENENTECH : 3rd-quarter profit rises
RE
GENENTECH : rejects Roche bid but willing to talk
RE
GENENTECH : rejects Roche bid
RE
GENENTECH : Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DNA Stock
  4. News Genentech, Inc.